Sanofi: Alnylam suspends fitusiran studies.
(CercleFinance.com) - Alnylam Pharmaceuticals, has provided an update on the clinical development program of fitusiran.
This is an investigational RNAi therapeutic in development for the treatment of hemophilia A and B with or without inhibitors.
As disclosed by Alnylam, a fatal thrombotic event occurred in a patient with hemophilia A without inhibitors enrolled in the Phase 2 Open Label Extension (OLE) study of fitusiran.
As a result, Alnylam, has suspended dosing in all ongoing fitusiran studies pending further review.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
This is an investigational RNAi therapeutic in development for the treatment of hemophilia A and B with or without inhibitors.
As disclosed by Alnylam, a fatal thrombotic event occurred in a patient with hemophilia A without inhibitors enrolled in the Phase 2 Open Label Extension (OLE) study of fitusiran.
As a result, Alnylam, has suspended dosing in all ongoing fitusiran studies pending further review.
Copyright (c) 2017 CercleFinance.com. All rights reserved.